There's a new frontier in treating autoimmune diseases. Today's treatments tamp down the friendly fire but don't fix what's ...

New data show that dual-target CAR T therapy induces durable remissions in children with high-risk B-cell leukaemia, offering ...

Early CAR T cell expansion is associated with both therapeutic activity and inflammatory toxicity, such as cytokine release syndrome and neurotoxicity. Routine flow cytometry can reliably track ...

A new international multicenter study published in the Journal of Cellular and Molecular Medicine provides important real-world evidence on the use of CD19-targeted chimeric antigen receptor (CAR) ...

CAR-T cell therapy has cured some children with blood cancers and is being studied in solid tumors, where responses differ due to how these cancers grow. CAR-T cell therapy has cured some children ...

CAR-T therapy was originally developed for leukemias and lymphomas, and the breakthrough treatment is now also being used for ...

CAR T-cell therapy re-engineers immune cells to target and eradicate high-risk blood cancers, offering potential cures where traditional chemotherapy fails. Initially requiring inpatient care due to ...

Lyell Immunopharma has acquired exclusive worldwide rights from Innovative Cellular Therapeutics (ICT) to LYL273, an advanced ...

Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...

Only a few dozen patients with lupus have been treated with CAR-T-cell therapy — but in a small German study, all five ...

The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence ...